Prot #MK-3475-164-02: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma

Project: Research project

StatusFinished
Effective start/end date12/16/1512/16/18

Funding

  • Merck Sharp & Dohme Corp. (Prot #MK-3475-164-02)